Latest news
Tissue-Agnostic Medicine Has a New Proof Point
The FDA has converted selpercatinib to traditional approval for RET fusion-positive solid tumours in adults and children. The decision strengthens tissue-agnostic precision oncology, but testing gaps still decide who is found.
The WHO’s first stroke resolution turns a clinical problem into a political one
The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda
A new guideline is changing how health systems think about obesity, diabetes and heart disease
IPM Brief – Issue 1 | The Last Mile Starts Here
Cancer Sequencing Becomes the Operating System of Precision Oncology
Personalised Cancer Vaccines Show Longer-Term Staying Power
Europe: the EU Cardiovascular Health Plan is becoming the “cancer plan” moment for heart disease
A new Lp(a) threshold could reshape cardiovascular risk assessment
The next cardiometabolic battleground is ultra-processed food
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.